As an innovative biotherapeutic drug, canakinumab (ILARIS) is widely used in the treatment of various inflammatory diseases, including periodic fever syndromes (CAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), familial Mediterranean fever (FMF), Still's disease, and gout, etc. The following will detail the administration methods, recommended doses, and precautions of canakinumab in the treatment of different diseases.

Dosage and Administration of Canakinumab (ILARIS)

Administration method: The administration of canakinumab is strictly limited to subcutaneous use. Both adult and pediatric patients need to receive the drug via subcutaneous injection. This administration method ensures that the drug can directly act on the subcutaneous tissue to achieve the best therapeutic effect.

Recommended Dose for Periodic Fever Syndromes (CAPS)

For CAPS patients, the recommended dose of canakinumab is individually adjusted according to the patient's weight. For patients weighing more than 40kg, the recommended dose is 150mg, administered subcutaneously once every 8 weeks. For patients with a weight between 15kg and 40kg, the recommended dose is 2mg/kg, also injected once every 8 weeks. For pediatric patients with an insufficient response, the dose can be increased to 3mg/kg, injected once every 8 weeks.

Recommended Dose for HIDS/MKD, FMF and Other Diseases

For patients with diseases such as TRAPS, HIDS/MKD, and FMF, the recommended dose of canakinumab is also adjusted based on weight. For patients weighing more than 40kg, the initial dose is 150mg, injected once every 4 weeks. If the clinical response is insufficient, the dose can be gradually increased to 300mg, injected once every 4 weeks. For patients weighing no more than 40kg, the recommended dose is 2mg/kg, injected once every 4 weeks, and the dose can also be adjusted to 4mg/kg according to the clinical response.

Recommended Dose for Still's Disease

For patients with Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA), the recommended dose of canakinumab is 4mg/kg (maximum dose not exceeding 300mg), administered subcutaneously once every 4 weeks to reduce the occurrence of adverse reactions.

Recommended Dose for Gout Flares

For adult patients with gout flares, the recommended dose of canakinumab is 150mg, administered as a single subcutaneous injection. For patients requiring retreatment, there should be an interval of at least 12 weeks before the new dose is administered.